Evidence map›Paper›PMID 39849453›Full record

ArticleJournal of nanobiotechnology2025

Synergistic anti-oxidative/anti-inflammatory treatment for acute lung injury with selenium based chlorogenic acid nanoparticles through modulating Mapk8ip1/MAPK and Itga2b/PI3k-AKT axis.

Huizhen Xing, Xinwei Bai, Xiaoying Pei, Yuqi Zhang, Xueying Zhang, Shujun Chen, Dan Li, Bin Lv, Xiaoying Wang, Xiaoli Wu

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Scutellarein fromPharmaceuticals (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huizhen XingSchool of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072, China.
Xinwei BaiSchool of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072, China.
Xiaoying PeiSchool of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072, China.
Yuqi ZhangKey Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Xueying ZhangSchool of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072, China.
Shujun ChenSchool of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072, China.
Dan LiCollege of Life Sciences, Nankai University, Tianjin, China.
Bin LvState Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. lyubin@tjutcm.edu.cn.
Xiaoying WangSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China. wxy@tjutcm.edu.cn.
Xiaoli WuSchool of Life Sciences, Faculty of Medicine, Tianjin University, Tianjin, 300072, China. wuxiaoli@tju.edu.cn.

Funding

Fundamental Research Funds for the Central Universities 63231049National Natural Science Foundation of China 82141213Tianjin Natural Science Foundation 22JCYBJC00460
6 · The paper itself

Abstract

Oxidative stress and inflammatory dysregulation play crucial roles in pathogenesis of acute lung injury (ALI), and their cyclic synergy drives excessive inflammatory responses and further exacerbates ALI. Therefore, new effective strategies to treat ALI are urgently needed. Herein, a novel synergistic selenium based chlorogenic acid nanoparticle was developed to disrupt the cyclic synergistic effect between oxidative stress and inflammatory response in ALI. The chlorogenic acid, a polyphenol commonly found in herb, had been effectively conjugated with human serum albumin and coated on selenium nanoparticles (Se NPs) to create CHSe NPs. The CHSe NPs exhibited superoxide dismutase(SOD) like and glutathione peroxidase(GPX) like activities, effectively scavenging various types of reactive oxygen species (ROS), and inhibited the inflammatory response of macrophages. Additionally, with excellent biosafety, CHSe NPs exhibited superior therapeutic effects in ALI mice models in vivo, surpassing the performance of the clinic drug dexamethasone. They remarkably reduced ROS levels, and elevated the SOD and GPX enzyme activities in lung tissue to exert antioxidant effects. In addition, the CHSe NPs modulated the immune microenvironment of ALI by reversing M1 macrophage polarization, downregulating the expression levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-a), nitric oxide synthase (iNOS), and myeloperoxidase (MPO), and upregulating anti-inflammatory cytokine (IL-10) levels, thereby alleviating excessive inflammation and decreasing neutrophil infiltration. Further mechanistic research revealed that CHSe NPs directly acted on and modulated the expression of Mapk8ip1 and Itga2b, which were upstream proteins of MAPK signaling pathway and PI3K-Akt signaling pathway, therefore impeding the cyclic synergy between oxidative stress and inflammatory dysregulation. In summary, CHSe NPs synergistically exert antioxidant and anti-inflammatory effects by regulating the MAPK signaling pathway and PI3K-Akt signaling pathway, showing enormous potential in the treatment of ALI.

Indexed as

Acute Lung InjuryAnti-Inflammatory AgentsAntioxidantsChlorogenic AcidNanoparticlesSeleniumAnimalsHumansMaleMiceMice, Inbred C57BLOxidative StressPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRAW 264.7 CellsReactive Oxygen SpeciesAnti-Inflammatory AgentsAntioxidantsChlorogenic AcidPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesSeleniumAcute lung injuryCHSe NPsInflammatory modulationROS scavengingSynergistic treatment

Identifiers

PMID39849453
PMCPMC11756189

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.